(Q35005139)

5 August 2017

1 reference

title

The pharmaceutical industry as a medicines provider (English)

1 reference

5 August 2017

David Henry

1

0 references

Joel Lexchin

series ordinal

2

object named as

Joel Lexchin

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

360

1 reference

5 August 2017

issue

9345

1 reference

5 August 2017

page(s)

1590-1595

1 reference

South African court battle damages drug industry's image

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911527-3

7 January 2021

Access to essential drugs in poor countries: a lost battle?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911527-3

7 January 2021

The pharmaceutical industry--to whom is it accountable?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911527-3

7 January 2021

Lessons from the glitazones: a story of drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911527-3

7 January 2021

Programmatic goals and approaches to onchocerciasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911527-3

7 January 2021

Drug donations must be strictly regulated. Georgia has tight guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911527-3

7 January 2021

Inappropriate drug donations: the need for reforms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911527-3

7 January 2021

Managing pharmaceutical expenditure while increasing access. The pharmaceutical management agency (PHARMAC) experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911527-3

7 January 2021

Wrong SIGN, NICE mess: is national guidance distorting allocation of resources?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911527-3

7 January 2021

Uneasy alliance--clinical investigators and the pharmaceutical industry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911527-3

7 January 2021

Conflict of interest in the debate over calcium-channel antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911527-3

7 January 2021

The quality of drug studies published in symposium proceedings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911527-3

7 January 2021

Evaluation of conflict of interest in economic analyses of new drugs used in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911527-3

7 January 2021

Success rates for new drugs entering clinical testing in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911527-3

7 January 2021

Cost of innovation in the pharmaceutical industry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911527-3

7 January 2021

Worldwide interest in global access to drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911527-3

7 January 2021

10.1016/S0140-6736(02)11527-3

Identifiers

DOI

1 reference

5 August 2017

1 reference